Results 31 to 40 of about 4,595,974 (209)

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves? [PDF]

, 2020
Although there are abundant data highlighting the safety and efficacy of direct oral anticoagulants, to date, recent guidelines have limited their use to stroke prevention in patients with non-valvular AF, as well as in the prevention and treatment of ...
Abdallah Almaghraby, Mahmoud Abdelnabi, Yehia Saleh   +2 more
core   +1 more source

Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension

Clinics, 2018
OBJECTIVES: Chronic thromboembolic pulmonary hypertension is one of the most prevalent forms of pulmonary hypertension and is a major complication of acute pulmonary embolism.
Francisca Alexandra Gavilanes-Oleas, Jose Leonidas Alves Jr, Caio Julio Cesar Fernandes, Luis Felipe Lopes Prada, William Salibe Filho, Mario Terra Filho, Luciana Morinaga, Susana Hoette, Carlos Jardim, Rogerio Souza   +9 more
doaj   +1 more source

Safety of direct oral anticoagulants in patients with atrial fibrillation and high risk of stroke (review of literature)

Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2020
Review discusses the problem of non-vitamin K antagonist oral anticoagulants safety in patients with non-valvular atrial fibrillation. Bleeding risk assessment while applying anticoagulant therapy, preventive methods for major bleeding (intracranial ...
E. I. Baranova, V. A. Ionin, A. A. Katsap, O. S. Kolesnik, E. V. Lebedeva   +4 more
doaj   +1 more source

Are direct oral anticoagulants preferable to warfarin for the treatment of left ventricular thrombi? A Bayesian meta-analysis of randomized controlled trials

American Heart Journal Plus, 2021
Background: There is no clear consensus on the optimal choice of anticoagulant in patients with left ventricular thrombi (LVT). Given the potentially fatal complications associated with this disease entity, we performed a systematic review and meta ...
Ahmed Sayed, Mohanad Ghonim, Mohamed Ghonim, Ahmed K. Awad, Yehia Saleh, Omar M. Abdelfattah   +5 more
doaj   +1 more source

Diffuse MRI Edema Predicts Relapse in Cerebral Amyloid Angiopathy–Related Inflammation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify MRI predictors of relapse and quantify relapse and mortality risk in cerebral amyloid angiopathy–related inflammation (CAA‐RI). A secondary objective was to assess the association between mycophenolate mofetil use and relapse risk. Methods We performed a retrospective cohort study of 36 patients with CAA‐RI treated at the
G. Abbas Kharal, Gowtham Yerneni, Kim J. Griffin, Nicolas Thompson, Ken Uchino, Irene Katzan, Dolora Wisco, Abeer Farrag, Jayashree Sundarajan, Andrew Russman, M. Shazam Hussain   +10 more
wiley   +1 more source

Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's Disease

Advanced Science, EarlyView.
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung, Xu Wang, Bin Liu, Raktim Roy, Nancy Jaiswal, Ratan K. Rai, Yuichiro Takagi, Cen Gao, Lifan Zeng, Ho‐Yin Lo, Reagan K. Wohlford, Ryan K. Higgins, Bruce T. Lamb, Anantha Shekhar, Anita C. Bellail, Chunhai Hao   +15 more
wiley   +1 more source

Laboratory monitoring of direct oral anticoagulants (DOACs)-The perfect storm?

, 2017
Laboratory monitoring of direct oral anticoagulants ...
LIPPI, Giuseppe, Favaloro, Emmanuel J.
core   +1 more source

Direct oral anticoagulation in cancer patients

, 2021
Thrombosis is a leading cause of mortality in cancer patients. Cancer patients are at an increased risk of developing atrial fibrillation, and venous thromboembolism is a leading cause of mortality, especially in patients undergoing chemotherapy.
Carbone A., Russo V., Golino P., D'Andrea A., Nigro G., Bottino R., Liccardo B.   +6 more
core   +1 more source

A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study)

Haematologica, 2018
The outcomes of patients developing major bleeding while on oral anticoagulants remain largely unquantified. The objectives of this study were to: (i) describe the burden of major hemorrhage associated with all available oral anticoagulants in terms of ...
Laura Green, Joachim Tan, Joan K Morris, Raza Alikhan, Nicola Curry, Tamara Everington, Rhona Maclean, Khalid Saja, Simon Stanworth, Campbell Tait, Peter MacCallum   +10 more
doaj   +1 more source